MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
ADIL - Adial Pharmaceuticals Inc
$2.78
0.00(0.00%)5:00:00 AM 11/30/2021
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of treatment for addictions. Its lead product is AD04, a selective serotonin-3 antagonist for the treatment of alcohol use disorder. The company was founded in 2010 and is based in Charlottesville, Virginia.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
Stock Statistics
MarketCap57.5M
PE Ratio
PEG Ratio
P/B10.5
P/S (ttm)
Earning Growth (QoQ)
Revenue Growth (QoQ)
Short %6%
Held by Institutions %9%
1 Day Vol Adjusted Return1.6
1 Month Vol Adjusted Return-2.8
3 Month Vol Adjusted Return-7.1
6 Month Vol Adjusted Return1.2
20 Days SMA Price ZScore-1.3
50 Days SMA Price ZScore-1.5
12 -26 Days PPO-6.7
1 Month Average Short Volume Ratio49.0
1 Day Volume Change ZScore0.9
1 Month Daily Vol5.0
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    11/29/2021ADIL
    Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer

    PNV2 demonstrates reduction of metastases in animal modelCHARLOTTESVILLE, Va., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive pre-clinical data for PNV2 in an animal model of triple negative breast cancer (TNBC). Based on the strength of this data, Purnovate, Inc.,

    11/17/2021ADIL
    REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest Developments

    CHARLOTTESVILLE, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, reminds investors that it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call will be availab

    11/10/2021ADIL
    Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock Options

    Financing to support clinical trial pathway for non-opioid drug candidate for treatment of painCHARLOTTESVILLE, Va., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received funds and capital commitments totaling $1,255,000; $800,000 from the sale of shares of com

    11/9/2021ADIL
    Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

    CHARLOTTESVILLE, Va., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced it will host a conference call at 11:00 A.M. Eastern Time on Thursday, November 18, 2021 to provide a clinical update and discuss the latest business developments. The conference call may be accessed using

    11/3/2021ADIL
    Adial Appoints Renowned Pharmaceutical Executive Cary J. Claiborne to Board of Directors

    CHARLOTTESVILLE, Va., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary J. Claiborne to the Board of Directors, increasing the number of board members to seven. Mr. Claiborne previously served as CFO and board member of Indivior PLC, a publicly traded specialty pharmaceutical comp

    10/21/2021ADIL
    Adial Pharma-Backed Purnovate Selects PNV-5030 As Pain Management Candidate

    Adial Pharmaceuticals Inc (NASDAQ: ADIL) has announced data in a preclinical model of pain reduction. Based on the data, Adial's subsidiary Purnovate Inc selected PNV-5030 as the lead compound for its program to develop pain management drugs. PNV-5030 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects across several therapeutic indications. PNV-5030 has demonstrated more than 50 times greate

    10/21/2021ADIL
    Adial Announces Positive Pre-Clinical Data for Purnovate’s PNV-5030 as a Drug Candidate for the Treatment of Pain

    Results suggest potential of PNV-5030 as both a standalone and combination therapy to reduce or eliminate opioid use and achieve meaningful pain reduction Clinical trial expected to commence in 2022 CHARLOTTESVILLE, Va., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced positive data in a pre-clinical mo

    10/18/2021ADIL
    Adial Pharmaceuticals to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

    CHARLOTTESVILLE, Va., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that William Stilley, Chief Executive Officer and President of Adial Pharmaceuticals, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 at the Wyndham Gr